Curis Dirección

Dirección controles de criterios 3/4

El CEO de Curis' es Jim Dentzer , nombrado en Sep 2018, tiene una permanencia de 5.58 años. compensación anual total es $1.66M, compuesta por 38.1% salario y 61.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.1% de las acciones de la empresa, por valor de €83.79K. La antigüedad media del equipo directivo y de la junta directiva es de 4.7 años y 9.7 años, respectivamente.

Información clave

Jim Dentzer

Chief Executive Officer (CEO)

US$1.7m

Compensación total

Porcentaje del salario del CEO	38.1%
Permanencia del CEO	5.7yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	9.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jim Dentzer en comparación con los beneficios de Curis?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$2m	US$634k	-US$47m
Sep 30 2023	n/a	n/a	-US$47m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$3m	US$615k	-US$57m
Sep 30 2022	n/a	n/a	-US$59m
Jun 30 2022	n/a	n/a	-US$57m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$3m	US$590k	-US$45m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$2m	US$545k	-US$30m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$2m	US$510k	-US$32m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$32m
Dec 31 2018	US$2m	US$479k	-US$33m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$43m
Mar 31 2018	n/a	n/a	-US$48m
Dec 31 2017	US$2m	US$443k	-US$53m

Compensación vs. Mercado: La compensación total de Jim($USD1.66M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD406.04K).

Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.

CEO

Jim Dentzer (56 yo)

5.7yrs

Permanencia

US$1,662,978

Compensación

Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
James Dentzer	President	5.7yrs	US$1.66m	0.10% $ 92.7k
Diantha Duvall	CFO and Principal Financial & Accounting Officer	1.8yrs	US$1.01m	0.011% $ 9.8k
Jonathan Zung	Chief Development Officer	less than a year	US$1.04m	0% $ 0
Mark Noel	Vice President of Technology Management & Intellectual Property	15.7yrs	US$413.39k	sin datos
Robert Martell	Chief Scientific Officer	no data	US$1.17m	0% $ 0
Elif McDonald	VP of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Reinhard von Roemeling	Senior Vice President of Clinical Development	4.8yrs	sin datos	sin datos

4.8yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CUS0 se considera experimentado (4.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Dentzer	President	5.7yrs	US$1.66m	0.10% $ 92.7k
Martyn Greenacre	Independent Chairman of the Board	24.3yrs	US$158.70k	0.022% $ 19.9k
Marc Rubin	Independent Director	13.9yrs	US$123.70k	0.024% $ 21.9k
Kenneth Kaitin	Independent Director	20.5yrs	US$126.20k	0.024% $ 21.4k
John Hohneker	Independent Director	2.4yrs	US$106.20k	0% $ 0
Anne Borgman-Hagey	Independent Director	1.6yrs	US$103.70k	0% $ 0

9.8yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CUS0 se considera experimentada (9.7 años de antigüedad promedio).

Curis Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc., Annual General Meeting, May 26, 2022

Recent updates

First quarter 2024 earnings released: US$2.05 loss per share (vs US$2.39 loss in 1Q 2023)

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Curis, Inc., Annual General Meeting, May 21, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$8.96 loss per share (vs US$12.14 loss in FY 2022)

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2022)

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$0.61 loss per share (vs US$0.50 loss in FY 2021)

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2021)

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 2Q 2021)

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021)

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020)

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.28 loss in 1Q 2020)

Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

Full year 2020 earnings released: US$0.61 loss per share (vs US$0.97 loss in FY 2019)

Curis, Inc. to Report Q4, 2020 Results on Mar 16, 2021

Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Curis Announces Initiation of Investigator-Sponsored Phase 2 Lucas Study of Ca-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

New 90-day high: €7.25

New 90-day high: €6.70

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $147.500001 million.

Curis, Inc. Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

New 90-day high: €1.17

Third quarter 2020 earnings released: US$0.11 loss per share

Curis, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Curi Announces Appointment of Jason Sandner as its Next Chief Executive Officer, Effective July 1, 2021

Curis, Inc. Announces Abstract for CI-8993 Accepted for Presentation At the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting

New 90-day low - €0.74

First half earnings released

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million.

Curis, Inc. to Report Q2, 2020 Results on Aug 04, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media